Circulating eosinophils emerge as a recurrence biomarker in common breast cancer
Hormone receptor-positive, HER2-negative breast cancer remains the most common breast cancer subtype, yet routine follow-up still lacks a simple blood-based marker that can help separate patients who are likely to recur from those who are not. This study places circulating eosinophils in that gap. Across discovery and validation cohorts, higher preoperative eosinophil counts tracked with better recurrence-free and distant metastasis-free survival, pointing to a biomarker signal that is measurable, repeatable, and tied to outcomes that matter in day-to-day oncology practice.
The biological pattern is not superficial. Elevated eosinophils aligned with lower human leukocyte antigen homozygosity and greater intratumoral immune activation, a combination that suggests the host immune system is not merely present but actively engaged against the tumor. In parallel, functional work linked eosinophils to antitumor activity with evidence of CD8+ T-cell involvement. This matters because recurrence in hormone receptor-positive disease is often driven by an immunologically quiet tumor environment, where malignant cells persist despite endocrine therapy and later reappear as distant disease. A biomarker that reflects immune activation rather than only tumor burden could therefore offer a different view of risk.
The discovery cohort included 472 patients, and the validation effort expanded to 23,170 patients with propensity score overlap weighting to reduce confounding. The association held across that broader population. Such consistency is important in a subtype where prognostic tools already exist, but many are either tissue-based, expensive, or not easily repeated over time. A peripheral blood count can be drawn before surgery, before adjuvant escalation, and during follow-up without adding major procedural burden.
Higher eosinophil counts also correlated with reduced recurrence risk beyond what is typically captured by routine clinicopathologic assessment. The study did not treat eosinophils as an isolated curiosity; instead, it tested whether they could perform as a clinically applicable liquid biopsy marker in a disease where biologic heterogeneity often hides behind a deceptively uniform receptor profile. The signal was strongest when recurrence and distant spread were the outcomes, not just a general survival proxy.
Immune activation, lymphocyte clustering, and preclinical tumor control
Mechanistic work strengthened the clinical associations. Integrated multiomics and spatial digital pathology pointed to an immune-rich microenvironment, with tumor-infiltrating eosinophils predominantly coaggregating with lymphocytes. That spatial relationship is not incidental. Immune cells that cluster together inside tumors are often participating in coordinated signaling rather than passing by one another in isolation. In this setting, eosinophils appear to sit within an antitumor network that includes lymphocytes rather than functioning as a passive blood marker with no tumor-level relevance.
The preclinical data were unusually direct. Eosinophil adoptive transfer reduced tumor burden in both the EMT6 BALB/c model and the E0771 C57BL/6 model. Using two distinct immunocompetent mouse systems strengthens the argument that eosinophils can influence tumor control across different biological contexts, not only in one narrow experimental setup. CD8+ T-cell involvement further supports a plausible mechanism: eosinophils may amplify or organize cytotoxic immune responses that constrain residual disease, which is especially relevant in breast cancers that relapse after apparently successful local and systemic treatment.
A single blood count does not explain all of that biology, but it may capture the sum of it. Eosinophils are part of the systemic immune milieu, and in this study they mirrored a state of immune readiness rather than immune silence. For clinicians, the practical implication is straightforward: a patient with higher eosinophils before surgery may carry a different immune context than a patient with low counts, even if both tumors share the same receptor subtype.
Added value beyond the 21-gene recurrence score and CDK4/6 therapy selection
The most clinically consequential part of the analysis may be the interaction with adjuvant treatment decisions. Among 2,973 patients with 21-gene recurrence scores, eosinophil levels added prognostic value beyond the score itself. That is an important finding because the recurrence score is already used to guide escalation and de-escalation decisions in hormone receptor-positive disease. If a blood-based marker improves risk separation on top of that tool, it could eventually help refine who needs more intensive therapy and who can be spared overtreatment.
The biomarker signal went one step further in 3,471 high-risk patients: eosinophil levels predicted which subset derived greater benefit from adjuvant CDK4/6 inhibitors. This is where the study moves from prognosis toward treatment prediction. Prognostic markers tell us who is at higher risk; predictive markers tell us who benefits from a specific therapy. Those are not the same thing, and the distinction carries real therapeutic consequences. In a setting where CDK4/6 inhibition adds toxicity, cost, and treatment complexity, a simple blood-based tool that enriches for benefit would be clinically valuable if confirmed prospectively.
The data do not justify routine change in practice on their own. They do, however, create a credible translational path. Eosinophils were evaluated as a preoperative biomarker, validated in a very large independent cohort, and then tested against established recurrence scoring and adjuvant therapy benefit. That sequence gives the findings more weight than a single exploratory signal would have on its own.
What this means for risk stratification in hormone receptor-positive breast cancer
The study reframes eosinophils as more than an incidental differential count on a complete blood count. In hormone receptor-positive/HER2-negative breast cancer, they may function as a blood-level readout of systemic immune activation and intratumoral immune engagement. The association with lower recurrence, the add-on value to the 21-gene score, and the link to CDK4/6 inhibitor benefit all point in the same direction.
Still, several clinical questions remain unresolved. The study identifies association, validation, and biologic plausibility, but it does not establish a universal cutoff that can be applied immediately in the clinic. It also leaves open how eosinophil levels behave alongside other inflammatory markers, whether they fluctuate over the course of treatment, and how they should be integrated with existing pathology and genomic assays in a reproducible decision algorithm. Prospective testing will be needed before eosinophils can move from promising biomarker candidate to routine risk tool.
Even so, the core message is difficult to ignore. In a disease subtype defined by its frequency and its recurrence risk, a readily available immune marker carried information about both prognosis and treatment benefit. That makes circulating eosinophils one of the more clinically grounded blood-based signals reported for hormone receptor-positive, HER2-negative breast cancer in recent years.